While the importance of prophylaxis for patients with HIV not on cART and with a CD4 count below 200 cells/μL is without a doubt, the dose and duration of corticosteroid therapy above which the dose and duration of corticosteroid therapy above which the benefit to risk ratio of PCP prophylaxis becomes positive is not well-established. This evidence concerns the gene CD4 and pneumocystosis.